

General Medicine

Volume - 4

MARROW
— Super Speciality

Instructions

- The notes must be used in conjunction with the Marrow SS Medicine videos and should not be considered standalone material.

Please note:

- The information in this book has been printed based on the transcript of the Marrow SS Medicine videos.
- The information contained in this book is for educational purposes only. The content provided is not intended to substitute for professional medical advice, diagnosis or treatment.
- This book cannot be sold separately. It has been made available to only select eligible users who have an active subscription to Marrow SS Medicine videos.
- The text, images, slides, and other materials used in this book have been contributed by the faculty, who are subject matter experts. We have merely reproduced them as video transcripts in this book.
- The notes have been consciously designed in a way that is concise and revisable. To ensure this, we have intentionally added only the most relevant modules and images that are needed for you.
- Reasonable care has been taken to ensure the accuracy of the information provided in this book. Neither the faculty nor Marrow takes any responsibility for any liability or damages resulting from applying the information provided in this book.
- This set contains notes of all main videos published in the app until Jan 2025. You can find notes for any additional videos published after this date within the app under the videos section.

All Rights Reserved

No part of this publication shall be reproduced, copied, transmitted, adapted, modified or stored in any form or by any means, electronic, photocopying, recording or otherwise.

© Marrow

//ME801SS-SAP

Volume - 4

Rheumatology and Immunology

232. SLE : Etiopathogenesis	1309
233. SLE : Immunological Basis	1313
234. SLE : Lupus Nephritis	1318
235. SLE : Clinical Presentation	1323
236. SLE : Organ System Manifestations	1328
237. SLE : Management	1331
238. Drug-Induced Lupus Erythematosus	1334
239. Antiphospholipid Syndrome	1335
240. Sjogren's Syndrome	1340
241. Systemic Sclerosis	1349

242. IgG4 Related Disease	1360
243. Sarcoidosis	1364
244. Overlap Syndrome	1376
245. Basics of Rheumatoid Arthritis	1378
246. Approach To Arthritis : I	1383
247. Approach To Arthritis : II	1386
248. Articular Features of Arthritis	1389
249. Extra Articular Features of Arthritis	1393
250. Treatment of Arthritis	1398
251. Spondyloarthritis	1401
252. Crystal Arthropathies	1418
253. Classification of Vasculitis	1435
254. Small Vessel ANCA Vasculitis	1437
255. Medium Vessel Vasculitis	1447
256. Large Vessel Vasculitis	1452
257. Variable Vessel Vasculitis	1464
258. Immune Complex Mediated Vasculitis	1468

Respiratory Disorders

259. Functional Anatomy of Lung	1475
260. Mechanics of Breathing	1488
261. Pulmonary Function Test - Interpretation	1495
262. Pulmonary Function Test - DLCO	1500
263. Flow Volume Curve	1503
264. Diagnosis of Tuberculosis	1508
265. Treatment of Tuberculosis	1515
266. Chronic Obstructive Pulmonary Disease	1518
267. Bronchial Asthma	1526
268. Allergic Bronchopulmonary Aspergillosis	1538

269. Hypersensitive Pneumonitis	1544
270. Eosinophilic Lung Disease	1548
271. Bronchiectasis	1555
272. Respiratory Failure	1562
273. Acute Respiratory Distress Syndrome	1565
274. Pulmonary Hypertension	1569
275. Venous Thromboembolism	1577
276. Interstitial Lung Disease	1589
277. Occupational Lung Disorders	1600
278. Obstructive Sleep Apnea Syndrome	1607
279. Effusion/Empyema	1610

Acid Base Regulation

280. Methodology and Interpretation of Abg Analysis	1616
281. Metabolic Alkalosis	1624
282. Case Scenarios on ABG	1626
283. Mineral Deficiencies	1637

ECG

284. Introduction To ECG	1639
285. Approach To Hypertrophy and Blocks	1648
286. AV Blocks	1663
287. SA Nodal Dysfunction	1674
288. Atrial Fibrillation and Flutter	1684
289. Tachyarrhythmias	1697
290. Ventricular Arrhythmias	1717
291. WPW Syndrome	1727
292. Introduction To ACS	1732
293. ACS : Coronary Circulation and Localization	1751
294. ACS - Evaluation and Management	1769

Biostatistics

295. Introduction To Data in Biostatistics	1783
296. Measures of Central Tendency and Variation	1785
297. Normal Distribution Curve	1788
298. Concept of Probability Value	1791
299. Tests of Significance	1794
300. Correlation, Regression and Skew	1795
301. Sampling Methods and Calculation	1799
302. Probability and Tiles	1803
303. Graphs	1806
304. Biostats Review and QA Round	1819
305. Analytical Epidemiology	1827
306. Advanced Analytical Study Designs	1829
307. Experimental Epidemiology	1832
308. Evidence Based Medicine	1838
309. Advanced Concepts in Screening of Diseases	1842

SLE : ETIOPATHOGENESIS

----- Active space -----

Connective tissue disorders

00:01:10

Chronic multisystemic autoimmune inflammatory connective tissue disorders.

- Rheumatoid arthritis (mc).
- Sjogren syndrome (2nd mc).
- Systemic Lupus Erythematosus.
- Antiphospholipid antibody syndrome (APS).
- IgG4 related disorders.
- Scleroderma.
- Inflammatory muscle diseases :
- Polymyositis.
- Dermatomyositis.
- Overlap syndrome.

Systemic lupus erythematosus (SLE)

00:05:48

World lupus day : may 10.

Female : male = 9 : 1.

Disease of females in the reproductive age group because SLE is driven by estrogen.

male SLE : Poor prognosis.

Childhood SLE : 100% renal involvement (lupus nephritis).

Very strong family history present.

Positive concordance of >40 % among identical twins.



List of diseases with female male ratio of 9 : 1 includes :

- Systemic lupus erythematosus.
- Sjogren's syndrome.
- Takayasu's arteritis.
- Primary biliary cirrhosis.
- Chronic fatigue syndrome.

----- Active space -----

Risk factors of SLE

00:16:18

Genetic risk factors :

Complement deficiency :

- Strongest genetic risk factor of SLE : **Early component deficiency : $C_{1q} > C_3 > C_4$.**
- TREX gene mutation (present on chromosome 3).
- **HLA DR B₁03 , DR B₁02.**
- HLA DR3 : Subacute cutaneous lupus.

Note : late complement deficiency predispose to **Neisseria and Toxoplasma infection.**


Environmental risk factor :

Important only in people affected with any genetic risk factors.

- OCP & HRT.
- UV B rays.
- Epstein Barr virus.
- Smoking.
- Slicosis
- Deficiency of vitamin D.

Pathogenesis of SLE

00:21:31



Immune dysregulation :

----- Active space -----


Type 3 hypersensitivity reaction (Immune complex mediated disease)

1. Defective clearance of apoptotic debris or defective lymphocytic phagocytosis.
2. Inefficient degradation of DNA containing neutrophil extracellular traps (NET) : Defective NETosis.
3. Innate immune system activation :

Central key pathogenic cytokine : IFN-alpha or Type I IFN.

Produced by lymphoid dendritic cell (plasmacytoid dendritic cell).

Genetic signature of SLE : upregulation of genes due to IFN alpha.




vessel wall : Vasculitis.

Joints : Arthritis.

Glomeruli : Glomerulonephritis.

----- Active space -----

Contributors to systemic lupus erythematosus (SLE) pathogenesis



Activation of B cell

00:33:32

T cell activates B cell by multiple pathways :

- IL 4 pathway.
- IL 12/21 pathway.
- CD 40 L - CD 40 interaction.

SLE : IMMUNOLOGICAL BASIS

----- Active space -----

Autoantibodies in SLE

00:00:08

- Antibodies start to appear 3 years before the onset of the clinical features.
- Autoantibodies in SLE : **Antinuclear antibodies (98%)**, anti-dsDNA (70%), Anti-Sm (25%), anti-RNP, Anti-Ro (SS-A), Anti-La (SS-B), Antihistone, Antiphospholipid, Antierythrocyte, Antiplatelet, Antineuronal (includes antiglutamate receptor), Antiribosomal P.
- Antinuclear antibodies forms the **best screening tests for all autoimmune diseases**, repeated negative tests make SLE unlikely.

ANA/Anti nuclear antibodies

00:01:11

Screening test for Connective Tissue Disorders (CTD).

Antibodies against the nucleus, nucleoplasm, mitotic spindle, small nuclear riboproteins, cytoplasmic organelles.

97% of the patients with SLE are ANA positive.

- methodology : **Indirect immunofluorescence** (gold standard), human epithelial-2/Hep-2 (derived from the laryngeal epithelial cells of laryngeal CA patients) cell line is used.
- Titre : Standard dilution $\geq 1:80$, 1:160, 1:320, 1:640, 1:1280.
- Intensity : (1+) (2+) (3+) (4+).
- Pattern.

Diagnosis of lupus : Following ANA positivity, **ANA profile** by immunoblot is preferred rather than ENA.

Two important tests to be done after ANA (specific tests) :

- Anti ds DNA.
- Anti smith.

Specificity : **Anti smith** > Anti ds DNA.

But clinically, **anti-ds DNA** is more important because :

- **Anti-ds DNA** : 75% of the patients with SLE have anti- ds DNA positive whereas only 25% of the patients with SLE have anti-smith DNA positivity.
- Anti-ds DNA titres correlates to **disease activity** in SLE.
- Anti-ds DNA \rightarrow increased **risk for nephritis & vasculitis**.

----- Active space -----

ANA pattern :

It may suggest the antibody which can appear in the antibody profile.

- Homogenous pattern : anti-ds DNA.
- Coarse speckled pattern : anti-Smith.
- Dense fine speckled pattern (DFS pattern) : r/o CTD.
- Fine speckled pattern : Sjogren's syndrome.

Antibodies checked under ANA profile

Anti Sm	Specific
Anti UIRNP	
Anti SSA	
Anti SSB	
Anti Histone	Drug induced lupus
Anti ds DNA	Specific
Anti Nucleosome	Specific
Anti Ribosomal P Protein	Neuro psychiatric lupus
Anti Centromere	
Anti Jo 1	
Anti mi 2	
Anti Ku	Lupus association
Anti PCNA	Lupus association
Anti Pm Scl	

Antibodies checked under ENA profile (Extractable Nuclear Antigen profile) :

Antibody	Specific disease
Anti Sm	Specific for Lupus(10-44%)
Anti- UI RNP	mCTD
Anti SSA (anti Ro)	Sjogrens
Anti SS B (anti La)	Sjogrens
Anti Scl 70	Scleroderma
Anti Jo 1	myositis

Anti-Ro and anti- La antibodies

00:13:45

Anti-Ro (SS-A) and anti-La (SS-B) positivity indicates **secondary Sjogren's syndrome** (associated with CTD).

m/c CTD association of Sjogren's : Rheumatoid arthritis.

2nd m/c association of Sjogrens : SLE.

Anti-Ro (SS-A) and anti-La (SS-B) positivity :

- **ANA negative lupus (3% cases)** definitely has anti-Ro positivity (so, look for Anti-Ro-52 antibody in ANA negative lupus to completely rule out SLE).
- Indicates **secondary Sjogren's syndrome**.
- Indicates **good prognosis** (Associated with decreased risk for nephritis and vasculitis).
- In pregnancy, it indicates the risk for **neonatal lupus** with congenital heart block.

----- Active space -----

- Associated with subacute cutaneous lupus erythematosus/**SCLÉ** (photosensitive).
- Associated with **shrinking lung syndrome**.
- Normally, Ro-52 antigen is protective in the skin and myocardium (so, anti-Ro 52 is linked to SCLÉ and **myocarditis**).

Anti U1 RNP (ribonucleoprotein) antibody

00:19:28

Associated with syndromes that have **overlap features** of several rheumatic syndromes including SLE.

It indicates mixed Connective Tissue Disease (**MCTD**).

ANA antibody will be positive with **coarse speckled pattern**.

Conditions with 100% ANA positivity :

- **MCTD**.
- Autoimmune hepatitis type I (**AIH type I**).
- Drug Induced Lupus Erythematosus (**DILE**).

Anti- histone antibody

00:22:18

Seen in **drug induced lupus**.

Homogenous ANA pattern indicates either :

- Antihistone positivity : **DILE**.
- Anti-ds DNA positivity : **SLE**.

Antiphospholipid antibody :

- Associated with **antiphospholipin syndrome/APS**.
- **1/3rd** of the patients with SLE have APS (thrombosis).

Anti - RBC/erythrocyte antibody

00:24:25

Anti-RBC/erythrocyte antibodies can be present in SLE causing autoimmune hemolytic anemia/AIHA (**Ig G mediated warm antibody**).

Antiplatelet antibody

00:31:14

Idiopathic thrombocytopenic purpura/ITP : Patient presents with thrombocytopenia and bleeding.

- Primary ITP.
- Secondary ITP, main causes : SLE, HIV, HCV.

----- Active space -----

Blood related presentations of SLE are common :

- AIHA (due to antierythrocyte antibody).
- ITP (due to antiplatelet antibody).

Neuronal antibodies in SLE

00:35:12

- **Antineuronal antibody/anti-glutamate antibody** : m/C antibody seen in neuro SLE.
- **Antiribosomal-P antibody** : Correlates with depression/ psychosis in CNS lupus (helps to differentiate b/w depression d/t neuro lupus & functional depression in SLE).

m/C neurological manifestation in SLE : **Cognitive dysfunction.**

Reading an ANA report :

- methodology : Indirect immunofluorescence.
- Standard dilution : 1:80 <<.
- Intensity : 1+, 2+, 3+, 4+.
- Pattern : Coarse speckled, cytoplasmic staining.

Other ANA patterns

00:39:11

Cytoplasmic pattern :

- Suggests **anti Jo-1 antibody.**
- Antisynthetase syndrome, seen in inflammatory muscle diseases.

Centromere pattern :

- **Anticentromere antibody.**
- CREST syndrome.

Nucleolar pattern :

- Overlap syndrome (**Pm/SLE-70 overlap** : Polymyositis scleroderma overlap).

ANA and ANA profile in a lupus patient should not be repeated periodically because they just help in classifying the disease as SLE and not useful as prognostic markers.


Biomarkers in SLE

00:41:56


- ESR :
Non-specific elevation.
Almost 90% of lupus have an increased ESR.
Can monitor disease activity.
- **CRP** : Low in active lupus (due to the presence of anti-CRP antibody and suppression of CRP by INF α).

- Anti-ds DNA antibody : To assess the disease activity/flare.
- Anti C1 Q antibodies : To assess nephritis.
- Complement C3 and C4 : SLE is characterised by low C3 and C4.
- ANA profile : To diagnose SLE.
- ENA profile : To diagnose SLE.


----- Active space -----




Dense speckled pattern



Coarse speckled pattern



Nucleolar pattern



Homogenous pattern

Centromere pattern

Fine speckled pattern

Anti-ds DNA :

3 major methodology :

- *Criethidiaae Luciliae* : Immunofluorescence (qualitative).
- Immunoblot : ANA profile (semiquantitative).
- ELISA : For repeat measurement (quantitative).

m/c pattern in SLE : Homogenous pattern.

most specific pattern in SLE : Homogenous/coarse speckled pattern.

m/c pattern in CTD : Fine speckled pattern.

SLE : LUPUS NEPHRITIS

Lupus nephritis

00:01:15

50 to 60% of SLE patients have clinically significant Lupus Nephritis.

Involvement in Lupus Nephritis :

- Vascular component :
 - Not common.
 - Develop **Thrombotic Microangiopathy** : Small vessel disease of kidney.
 - Associated with **Anti Phospholipid Syndrome**.
- Glomerular component :
 - Commonly Seen.
 - mainly Involved.
- Tubulo Interstitial component : Rare .

Glomerular involvement in lupus nephritis .


Indication for biopsy :

urine $>$ Ig/day protein or 500 mg/dl with microscopic hematuria (\geq 3 RBC per HPF after urine centrifugation).

On suspicion of nephritis :

- The patient have to be assessed on URE (urine routine examination).
- URE to be done in all follow ups.

Classification of lupus nephritis (based on biopsy) :



Class 6 : Advanced sclerotic lupus nephritis

----- Active space -----

Class 1 :

- minimal mesangial lupus.
- Normal in light microscope.
- Asymptomatic .
- No treatment required and good prognosis.

Class 2 :

- mesangial Proliferative lupus.
- mesangial Proliferation seen in light microscope.
- Asymptomatic.
- No treatment needed & good prognosis .


Immunofluorescence in both Class 1 & Class 2 : mesangial Immune Complex deposition seen and hence cannot be differentiated.

Class 5 :

- membranous Lupus.
- Difficult to treat.
- Steroid refractory.
- Better prognosis than class 4 as lesser chance for CKD.
- Presentation : Adult Onset Nephrotic Syndrome.

manifestations :

- Progressive facial puffiness , pedal edema.
- Insidious onset.
- RFT normal .
- URE : Presence of albumin.
- Increased total cholesterol.



----- Active space -----

Class 3 and 4 : Proliferative Lupus Nephritis .

Class 3 : Focal Proliferative Lupus Nephritis : < 50 %.

Class 4 :

- Diffuse Proliferative Lupus Nephritis : > 50 %.
- **worst prognosis** as develops CKD .


Global : Entire complete involvement.

Segmental : In part involvement.

Presents with **Type 2 RPGN**.


- Within days to weeks develops renal failure.
- High coloured urine +.
- Within week : Facial puffiness, pedal edema develops & progresses, reduced urine output.

membranous nephropathy : Thickened glomerular basement membranes (thick capillary loops) :




membranous nephropathy

Class IV : Glomerulus showing thickened capillary loops and membranes.




membranous nephropathy




Diffuse proliferative
lupus nephritis (class IV)

Case HP :



----- Active space -----




Complete proliferation :



RPGN class IV



----- Active space -----

In class 3 & 4 SLE : IgG, IgA, Kappa Lambda, C₁q, C₃.

Immunofluorescence showing full house effect

In Class 4 : wire loop due to subendothelial deposition.

most specific finding : In electron microscopy hematoxylin bodies of gross.

R/o in :

- PUO & female of reproductive age group
- Fever+ fatigue + weightloss, hairloss.
- Female + fever + arthritis.
- Female + DAH presentation.
- Female + mesenteric/ CNS vasculitis.
- Female + adult onset nephrotic syndrome.
- Female + RPRF.
- Female + stroke.
- Female + rapid progressive anemia.
- Female + bleeding & thrombocytopenia.